Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Greinix, HT; Attarbaschi, A; Girschikofsky, M; Greil, R; Holter, W; Neumeister, P; Peters, C; Petzer, A; Rudzki, J; Schlenke, P; Schmitt, CA; Schwinger, W; Wolf, D; Worel, N; Jaeger, U.
Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network.
MEMO-MAG EUR MED ONC. 2020;
Doi: 10.1007/s12254-020-00582-4
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Greinix Hildegard
- Co-Autor*innen der Med Uni Graz
- Neumeister Peter
- Schlenke Peter
- Schwinger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers.
- Find related publications in this database (Keywords)
- CAR-T cells
- Position statement
- Network
- Patient selection criteria
- Infrastructure requirements